Browsing Centre for Microvascular Research (CMR) by Author "Walter, RJ"
Now showing items 1-1 of 1
-
CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues.
Yu, X; Munoz-Sagredo, L; Streule, K; Muschong, P; Bayer, E; Walter, RJ; Gutjahr, JC; Greil, R; Concha, ML; Müller-Tidow, C (2021-06-03)Acute myeloid leukemia (AML) has a poor prognosis under the current standard of care. In recent years, venetoclax, a BCL-2 inhibitor, was approved to treat patients, ineligible for intensive induction chemotherapy. Complete ...